Komori
Astellas Pharma (4503) · InitiativeAchieved

Development of the anti-CD40 monoclonal antibody bleselumab discontinued

First written in FY2022-Q1. 1 of 1 entries say "Achieved", first in FY2022-Q1. Latest entry: FY2022-Q1.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Discontinuation of Bleselumab DevelopmentA theme 1 companies write about · 1 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2022-Q1AchievedAnnual report

    「「その他の費用」として、開発プロジェクトの中止に伴う減損損失（DNAワクチンASP0892：215億円、抗CD40モノクローナル抗体bleselumab：41億円）を計上したことなどにより、フルベースの業績はコアベースの業績と比較して減益幅が大きくなりました。」

    抗CD40モノクローナル抗体bleselumabの開発中止が開示され、これに伴い41億円の減損損失を認識した。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Astellas Pharma's next results are scheduled for 2026-11-04. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.